China Medical System Holdings Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China Medical System Holdings Limited
5 Talking Points As Sun's Cequa Hits Home Turf And There's Restasis
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows
Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Shionogi Reveals Strategy For COVID-19 Drug Xocova
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
- Contract Research Organization-CRO
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CMS Aesthetics
- CMS Bridging Limited
- CMS Medical Hong Kong Limited
- CMS Medical Venture Investment Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.